Cohort baseline characteristicsa
| Characteristics | |
|---|---|
| Age at enrollment (yr) | 49 (26–61) |
| Sex | 11/31 Men (35%), 20/31 women (65%) |
| Disease subtype at enrollment | 21/31 (68%) RR, 7/31 (23%) SP, |
| 3/31 (10%) PP | |
| Disease duration at enrollment (mo) | 109 (8–461) |
| Patients with new relapses in past 30 days | 1/31 (3%) |
| No. of relapses in past year per subject | 0 (0–3) |
| Modified Fatigue Impact Scale score at enrollment | 43 (0–78) |
| Symbol Digit Modality Test at enrollment | 50 (35–81) |
| Expanded Disability Status Scale score at enrollment | 3 (1–6.5) |
| Immunomodulatory treatment status at baseline | |
| On treatment | 25/31 (81%) |
| Not on treatment | 6/31 (19%) |
| Treatment type at baseline | |
| Interferon | 3/25 (12%) |
| Glatiramer | 6/25 (24%) |
| Natalizumab | 2/25 (8%) |
| Teriflunomide | 1/25 (4%) |
| Fingolimod | 4/25 (16%) |
| Dimethyl fumarate | 9/25 (36%) |
| No. of subjects who switched between disease-modifying therapies from baseline to follow-up scans | 10/31 |
Note:—RR indicates relapsing-remitting MS; SP, secondary-progressive MS; PP, primary-progressive MS.
↵a Median values are shown with the range of observed values in parentheses.